MDxHealth SA (NAS:MDXH)

Full Year 2024 MDxHealth SA Earnings Call Transcript

Feb 26, 2025 / 09:30 PM GMT

Release Date Price: $1.83 (-6.15%)

Transcript

Key Points

Positve

MDxHealth SA (MDXH) achieved a 28% revenue growth for Q4 and the full year 2024, demonstrating strong financial performance.
The company reported a significant increase in test volumes, with tissue-based tests growing by 50% in Q4 and 31% for the full year.
MDxHealth SA (MDXH) maintained revenue growth without expanding its commercial sales organization, indicating increased productivity and market penetration.
The company has a unique market position in the urology diagnostic space, offering clinically actionable results post-biopsy.
MDxHealth SA (MDXH) is on track to achieve positive adjusted EBITDA in the first half of 2025, reflecting improved financial health.

Negative

Gross margins declined from 65.3% in Q4 2023 to 62.7% in Q4 2024, primarily due to test mix and timing of payments.
Operating loss for Q4 2024 was $4.6 million, although it showed a decline from the previous year, it still indicates ongoing financial challenges.
The company faces challenges in navigating the diagnostic pathway for patients, which remains complex and potentially confusing.
MDxHealth SA (MDXH) has not provided specific guidance on gross margins for the future, creating uncertainty for investors.
The company's growth strategy does not currently include significant contributions from new offerings like germline testing, which may limit immediate revenue diversification.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDXH.OQ - MDxHealth SA
Full Year 2024 MDxHealth SA Earnings Call
Feb 26, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the MDX Health 4th quarter and full year 2024 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key, followed by 0.

After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on a touch tone phone. To withdraw your question, please press star, then 2.

Please note this event is being recorded.

I would now like to turn the conference over to John Francis with Life SAI advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.